CRISPR vs Moderna: Market Cap Gap and Pipeline Outlook Contrast
Crispr Therapeutics AG trades at $47.78 with a $4.78B market cap, while Moderna trades at $61.82 with a $25.06B market cap, about 5.2 times larger. Both face losses, but CRISPR's Casgevy approval and Moderna's pipeline advances shape divergent analyst outlooks.
Crispr Therapeutics AG trades at $47.78 with a market cap of $4.78B, while Moderna, Inc. trades at $61.82 with a market cap of $25.06B, making Moderna about 5.2 times larger. Moderna is trading nearer its 52-week high, while Crispr Therapeutics is nearer its low. Both biotech firms are facing persistent losses but are advancing distinct therapeutic platforms.
Crispr Therapeutics AG reported a net loss of $581.60 million in 2025, with revenue declining sharply to $1 million in 2026. Recent news highlights FDA pediatric approval for Casgevy, its gene therapy, but financial performance remains weak amid high cash burn. The company's 52-week range is $44.34 to $76.78, with an enterprise value of $3.13B. Analyst consensus is bullish with a $74.50 price target, but fundamental risks include persistent losses, negative margins, and operational cash outflows. CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics, with its most advanced pipeline candidate, CTX001, developed in collaboration with Vertex Pharmaceuticals to target sickle cell disease and transfusion-dependent beta-thalassemia. The company is also progressing additional gene editing programs for immuno-oncology and a stem cell-derived therapy for Type 1 diabetes.
Moderna, Inc. posted 2025 revenue of $1.92B and a net loss of $2.82B, continuing revenue declines from pandemic peaks. The stock shows mixed technical signals with bullish overall momentum but bearish moving averages. Recent positive developments include advancing cancer immunotherapy trials and securing EU RSV vaccine contracts, providing potential growth catalysts beyond COVID-19 vaccines. Moderna's 52-week range is $22.36 to $81.80, with an enterprise value of $21.15B. Analyst consensus is cautious with a $49 price target below current levels, reflecting concerns about profitability timeline. Key risks include clinical trial outcomes, competitive pressure, and vaccine demand volatility. Moderna operates as a clinical stage biotechnology company focusing on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines for infectious, immuno-oncology, and cardiovascular diseases.